Executive Summary
Q2 FY27 results (quarter ended 30 September 2026) across the 50 filings show a sharply bifurcated Indian corporate landscape: revenue growth is broad and strong, but profit conversion is uneven.
Pharma and healthcare names (Zydus, Marksans, Biocon, Lenskart, Apollo Hospitals) delivered headline revenue growth of roughly 12-33% YoY, yet several saw margin compression from depreciation, freight, forex and mix shifts, with Biocon's net profit down 52% YoY on a weak Services segment and Zydus EBITDA margin falling from 32.9% to 24.0%. Industrials and auto components (NDR Auto, Diffusion Engineers, Vikram Thermo, Uniparts, Hariom Pipe, Indo Count) largely grew revenue 25-60% YoY, with mixed profitability as input costs, power costs and employee expenses rose faster than sales. Financials showed weaker earnings: JM Financial's consolidated profit fell about 11% YoY in Q2 and about 27% in H1, and Niva Bupa's solvency ratio dropped to 2.03 from 2.85 a year earlier after an IRDAI warning. The most critical developments are Electrotherm's negative-rated filing (quarterly loss, ongoing loan defaults, an Rs 1,148 crore liability understatement and an ED attachment), Suzlon's margin compression despite strong revenue, Apollo Hospitals' CEO transition, and the sharp rise in leverage at Lenskart-peer and capex-heavy names such as Advance Agrolife and JK Lakshmi Cement, whose net debt/EBITDA rose to 2.31 from 0.51.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Corporate action · Corporate governance · Board meeting · Company update
Tracking the trend? Catch up on the prior India Stock Market Daily Regulatory Digest digest from November 03, 2026.
Investment Signals (12)
- Indo Count Industries ↓ (BULLISH)▲
Consolidated revenue up 57.5% YoY to Rs 1,672.65 Cr and PAT up 237.9% YoY to Rs 131.9 Cr; cash rose to Rs 315.6 Cr from Rs 113.6 Cr at March 2026
- Lenskart Solutions ↓ (BULLISH)▲
Q2 FY27 revenue up 32.5% YoY to Rs 2,845 Cr and PAT more than doubled to Rs 232 Cr (about 105% growth), showing clear operating leverage; H1 PAT Rs 461 Cr
- Hariom Pipe Industries ↓ (BULLISH)▲
Standalone Q2 revenue up 65.0% YoY to Rs 554 Cr and PAT up 173.9% YoY to Rs 28.5 Cr, with sequential revenue growth of 29.1% QoQ despite the Tamil Nadu plant shutdown in Q1
- Manaksia Coated Metals ↓ (BULLISH)▲
Management guided FY27 revenue up 35%-55% over FY26, with the second colour coating line targeted for Q3 FY27 and Q2 total income up 43.8% YoY to Rs 321.55 Cr
- Suzlon Energy ↓ (BULLISH)▲
Q2 FY27 revenue up 27% QoQ to Rs 4,869 Cr and H1 revenue up 24% YoY to Rs 8,688 Cr; management guided H2 EBITDA at 1.5x-1.65x of H1, though YoY WTG margin compressed from 26.9% to 21.2%
- Nykaa (FSN E-Commerce) (BULLISH)▲
Q2 FY27 GMV up 30% YoY to Rs 6,151 Cr, PAT up 207% YoY to Rs 101 Cr, EBITDA margin expanded to 8.7% from 6.8%, and Fashion EBITDA margin turned positive at 0.2%
- Ellenbarrie Industrial Gases ↓ (BEARISH)▲
Revenue up about 28% YoY to Rs 1,143 Cr and H1 PAT up about 27% to Rs 706 Cr, but Q2 PAT fell about 2.9% YoY because power costs rose about 40% and depreciation about 37%
- JM Financial ↓ (BEARISH)▲
Consolidated Q2 net profit down about 11% YoY to Rs 240 Cr and H1 net profit down about 27% to Rs 531 Cr; mutual fund AUM for non-liquid schemes fell 7.2% YoY, though it ranked #1 by IPO/QIP deal value in H1 FY27
- Biocon Limited ↓ (BEARISH)▲
Q2 FY27 reported net profit fell 52% YoY to Rs 41 Cr, EBITDA fell 7% YoY to Rs 865 Cr, Services revenue fell 9% YoY and EBITDA margin contracted from 22% to 20%
- Niva Bupa Health Insurance ↓ (BEARISH)▲
Solvency ratio fell to 2.03 from 2.85 a year earlier and 2.25 in Q1, other comprehensive income turned to Rs -138.5 Cr on debt fair-value losses, and IRDAI imposed a six-month bar on opening new places of business
- Electrotherm (India) ↓ (BEARISH)▲
Standalone Q2 net loss of Rs 20.06 Cr (EPS Rs -15.74), half-year loss of Rs 13.20 Cr versus a prior-year profit, ongoing loan defaults and a new ED provisional attachment
- JK Lakshmi Cement ↓ (BEARISH)▲
Q2 PAT down 75% YoY to Rs 21 Cr, EBITDA down 26% YoY, capacity utilisation fell to 62% from 76%, and net debt/EBITDA rose to 2.31 from 0.51 at March 2026
Risk Flags (8)
- Electrotherm (India)/Governance and Solvency↓ [HIGH RISK]▼
Q2 loss of Rs 20.06 Cr, Rs 1,148.28 Cr understatement of liability to Rare ARC, ongoing loan defaults and new ED attachment; the filing also seeks to vary MD powers via postal ballot
- Biocon Limited/Earnings Quality↓ [HIGH RISK]▼
Other income fell 63% YoY to Rs 34 Cr while depreciation and amortisation rose 19% YoY to Rs 563 Cr, so reported net profit fell 52% YoY despite flat total income
- JK Lakshmi Cement/Leverage↓ [HIGH RISK]▼
Net debt rose to Rs 1,225 Cr from Rs 611 Cr at March 2026, net debt/EBITDA rose to 2.31x and capacity utilisation dropped to 62% from 76% a year earlier
- Suzlon Energy/Margin and Finance Cost↓ [MEDIUM RISK]▼
Consolidated EBITDA margin fell to 14.8% from 18.8% YoY and finance cost run-rate already exceeds the Rs 300 Cr H1 estimate, with about Rs 50 Cr of non-recurring Suzlon 2.0 costs
- Apollo Tyres/Profitability↓ [MEDIUM RISK]▼
Consolidated profit fell 19.3% YoY despite 16.7% revenue growth; profit before exceptional items fell 25.3% YoY, and the Europe segment result fell 46.1% YoY
- Advance Agrolife/Earnings Momentum↓ [MEDIUM RISK]▼
Quarterly PAT fell 47.7% QoQ to Rs 117.9 Cr and EPS fell to Rs 1.84 from Rs 3.50, with equity capital up to Rs 642.9 Cr from Rs 450 Cr, diluting per-share earnings
- Apollo Hospitals/Leadership and Cost Growth↓ [MEDIUM RISK]▼
CEO of the Hospitals Division (Dr. Madhu Sasidhar) ceases effective 14 November 2026, standalone other expenses rose 27.7% YoY versus 12.7% revenue growth, and trade receivables rose to Rs 4,256 Cr from Rs 3,485 Cr
- Uniparts India/Gross Margin↓ [MEDIUM RISK]▼
Gross margin fell to 65.7% from 69.4% YoY, EBITDA margin contracted QoQ to 23.1% from 25.3%, and large agriculture grew just 10% YoY against a roughly 17% industry volume decline
Opportunities (8)
- Nykaa/Simply Nam Acquisition (OPPORTUNITY)◆
Acquisition of an 82% stake in celebrity makeup brand Simply Nam, subject to approvals, alongside NYKAA NOW expansion to 15 cities with a 25+ city target by FY27 end
- Lenskart/Operating Leverage↓ (OPPORTUNITY)◆
PAT growth of about 105% against revenue growth of 32.5% indicates strong operating leverage, supported by in-house frame (+71.7%) and lens (+52.2%) manufacturing growth that offsets rupee depreciation
- Manaksia Coated Metals/Capacity Ramp↓ (OPPORTUNITY)◆
FY27 revenue guided 35%-55% higher, FY28 volumes of 175,000-200,000 tons, and solar plant expected to offset 50%-55% of Kutch grid power, lowering power cost exposure
- Hariom Pipe/Operating Recovery↓ (OPPORTUNITY)◆
Standalone PAT more than doubled YoY and revenue grew 29.1% sequentially in Q2 after the Q1 Tamil Nadu plant shutdown, suggesting capacity restoration is flowing through to earnings
- Rustomjee (Keystone Realtors)/Pipeline and Balance Sheet (OPPORTUNITY)◆
Ongoing residential GDV of Rs 203.4 Bn and forthcoming GDV of Rs 407.9 Bn, with gross D/E of 0.28x (net 0.04x) and an AA-/Stable rating from Crisil and ICRA
- NDR Auto Components/Order Book and Capacity Adds↓ (OPPORTUNITY)◆
Standalone order book of Rs 1,150 Cr after Rs 540 Cr of Q2 inflows, H1 PAT up 27.2% YoY, and new seat, latch and belt plants with SOP targets from January 2027
- Balrampur Chini Mills/Sugar Recovery↓ (OPPORTUNITY)◆
Q2 net profit more than doubled YoY to Rs 95.9 Cr and sugar segment PBIT rose to Rs 140.8 Cr from Rs 52.8 Cr, with a Rs 4.00 interim dividend declared
- Diffusion Engineers/Standalone Growth↓ (OPPORTUNITY)◆
Standalone Q2 revenue up 35.2% YoY to Rs 108 Cr and PAT up 53.7% YoY to Rs 15.2 Cr, with consolidated revenue up 50.7% YoY
Sector Themes (6)
- Revenue Growth Outpacing Profit Growth (HIGH IMPACT)◆
Across the set, most industrial and healthcare companies grew top line 15-60% YoY while profit grew more slowly or fell (Apollo Tyres, Zydus, Uniparts, JK Lakshmi, Biocon), with input costs, power, freight and depreciation the common drags; 7 of the 12 companies with disclosed margins showed YoY or QoQ margin compression
- Depreciation and Finance Cost Build-Up from Capex (HIGH IMPACT)◆
Capex-heavy names show rising D&A and finance costs (Biocon D&A +19% YoY, Ellenbarrie depreciation +37% and power +40%, Jtekt finance costs +196% YoY, Ravindra Energy financial costs +122%, Hariom finance cost +28%), with leverage rising at JK Lakshmi (net debt/EBITDA 2.31x) and Advance Agrolife (finance costs up 41%)
- Forex and Commodity Pass-Through Pressure (MEDIUM IMPACT)◆
Multiple filings cite rupee depreciation or commodity volatility as a margin headwind (Lenskart, Suzlon, EPACK Durable with a Rs 10 Cr forex loss, Zydus, Marksans), with pass-through lags delaying recovery; this makes Q3 margin trajectory dependent on contract resets
- Governance and Regulatory Overhang in Financials and Leisure (MEDIUM IMPACT)◆
IRDAI sanction on Niva Bupa, Electrotherm's ED attachment and loan defaults, and an exchange fine on Ircon for board composition non-compliance highlight rising regulatory and compliance scrutiny among PSUs and specialty financials
- Capital Raises and Equity Dilution (MEDIUM IMPACT)◆
Multiple companies raised fresh equity or are issuing warrants (Ravindra Energy Rs 2,013.6 Mn rights issue/ESOP, Advance Agrolife equity capital up to Rs 642.9 Cr, Esha Media warrants at Rs 15, Amanta and Gaja IPO fund deployments still largely unutilised), with per-share metrics diluted accordingly
- Leadership and CFO Transitions (LOW-MEDIUM IMPACT)◆
CFO or top executive changes at Apollo Tyres (Ravi Kumar Shingari), GMM Pfaudler (Ankit Nayyar, after early exit of Alexander Poempner), and Apollo Hospitals (CEO of Hospitals Division ceasing), signalling management turnover in large caps
Watch List (8)
-
Postal ballot on MD variation (term to 31 January 2031) plus pending resolution of Rare ARC liability and ED attachment; any further default or NCLT step could be decisive
-
H2 FY27 margin trajectory (guided at 1.5x-1.65x of H1 EBITDA) and WTG margin guidance of 22-23%; watch for the next earnings update on finance cost versus the Rs 300 Cr estimate
-
Transition of the Hospitals Division leadership effective 14 November 2026 and Cloudnine divestment completion on 3 November 2026; watch standalone other expense growth against revenue growth
-
Rail TEU volumes (target of at least 100,000 TEUs for the quarter) and Snowman's 23,000-pallet addition plan; Q1 hit means full-year double-digit growth is uncertain
-
Capacity utilisation recovery from 62% and deleveraging path from net debt/EBITDA of 2.31x; the next quarter's EBITDA trend will confirm whether the Q2 pricing and volume softness persists
-
Solvency ratio trajectory from 2.03 and the six-month bar on new places of business; watch Q3 fair-value movements on debt instruments
-
Sustainability of the PAT growth (about 105% YoY) given rupee headwinds, and H2 guidance on in-house manufacturing ramp (frames +71.7%, lenses +52.2%)
-
Second colour coating line commissioning targeted within Q3 FY27 and solar plant offset of Kutch grid power; any slip would challenge the 35%-55% FY27 growth guidance
Filing Analyses
(50)
04-11-2026
Zydus Lifesciences filed its Q2 FY27 earnings investor presentation on November 4, 2026, covering the quarter ended September 30, 2026. Total revenues rose 29% YoY to Rs 79,096 mn, with EBITDA of Rs 18,945 mn (24.0% margin) and reported PAT of Rs 9,255 mn, up 26.6% YoY, though EBITDA margin declined from 32.9% a year earlier and PAT grew more slowly than revenue. Net debt stood at Rs 51,998 mn, and organic capex for the quarter was Rs 4,655 mn.
- · USFDA inspections at SEZ II Ahmedabad (one observation) and Moraiya formulations facility (five observations) concluded
- · Transdermal product approval received for Moraiya site on October 21, 2026
- · Company received 12 ANDA approvals and filed 4 ANDAs in Q2 FY27; 5 new US products launched
- · Secondary sales growth in India was 20% YoY, with chronic and sub-chronic share at 56.9%
- · Net debt to EBITDA improved to 0.68x from 0.28x-range history as shown in trend chart, and net working capital rose to Rs 86,143 mn (Q2 FY26 comparison) versus Rs 75,938 mn in Q2 FY27
- · Consumer Wellness QoQ decline of 21.5% reflects sequential softness despite strong YoY growth
- · ESG rating reached 71/100 (Leader category, top 10%), with core ESG rating at 68/100 from 66/100
04-11-2026
Marksans Pharma Limited filed its Q2 & H1 FY27 earnings investor presentation on November 4, 2026. Q2FY27 revenue rose 30.5% YoY to ₹940 crore and EBITDA grew 48.3% to a record ₹214 crore, while PAT increased 44.8% YoY to ₹144 crore. However, the company's Rest of World (RoW) revenue fell 47.0% YoY to ₹14 crore amid West Asia disruption, and Q2 PAT declined 10.0% QoQ due to higher depreciation and amortisation, lower other income, and a higher effective tax rate.
- · US & North America revenue growth slowed to 8.7% YoY in Q2FY27 despite being a record quarter, and the company cited a softer US consumer environment
- · Q2FY27 PAT declined 10.0% QoQ due to higher D&A on acquired intangibles, lower other income from currency movements, and a 25.8% effective tax rate
- · Other expenses rose QoQ, including ~₹20 crore higher freight costs
- · Q2FY27 gross margin moderated QoQ to 58.5% from 59.1% in Q1FY27
- · Organic UK & Europe growth was 48.6% YoY but the company's Europe growth partly relies on QliniQ acquisition contribution (~₹40 crore in Q2FY27)
- · Working capital cycle was ~128 days in H1FY27 versus ~138 days in FY26
- · Net cash position was ₹1,095 crore after ₹95 crore M&A spend and ₹41 crore dividend in H1FY27
04-11-2026
Keystone Realtors Limited (trading as Rustomjee, scrip RUSTOMJEE) filed an investor presentation on its unaudited financial results for the quarter and half year ended September 30, 2026 (Q2FY27). The presentation highlights a pipeline of ~8.28 msf of ongoing saleable area and ~22.24 msf of forthcoming saleable area, with ongoing residential projects at a GDV of INR 203.4 Bn and forthcoming residential projects at INR 407.9 Bn. The filing itself contains no quantified period-over-period results, so the figures below are pipeline and balance-sheet metrics as presented.
- · Gross debt-to-equity is 0.28:1 and net debt-to-equity is 0.04:1
- · Credit rating of 'AA- / Stable' from Crisil Ratings and ICRA
- · Business development pipeline of ~INR 311 Bn GDV across 27 projects added since FY23
- · Ongoing projects under construction nearly doubled from 4.9 Mn sq ft to 8.3 Mn sq ft in about three years
- · Entered new micro markets including Igatpuri, Chembur, Mahim, Versova, Dombivli, Kasara, Nagpur, Sion, Lokhandwala, Sewri, Dindoshi, Goregaon East and Goregaon West
- · Pipeline includes 1.6 lakh (approx. 160,000) redevelopment-related housing societies in MMR and 70% to 85% of new supply in matured micro markets coming from redevelopment
- · Mt. K Kapital is a SEBI-approved Category II AIF; its first fund is an ESG impact fund anchored by State Bank of India and Famy Group, and a second fund is announced with Marubeni Corporation
- · Agreement signed with MHADA for redevelopment of GTB Nagar in Sion
04-11-2026
Biocon reported consolidated un-audited results for Q2FY27 (quarter ended September 30, 2026), with total income of Rs 4,423 Cr (+1% YoY), revenue from operations of Rs 4,389 crore (+2% YoY), and EBITDA of Rs 865 Cr (-7% YoY). Biopharma revenue rose 5% YoY to Rs 3,583 crore, but Services revenue fell 9% YoY to Rs 833 crore and EBITDA margin contracted to 20% from 22%. Reported net profit was Rs 41 Cr, down 52% YoY from Rs 85 Cr, while H1FY27 net profit rose 57% YoY to Rs 182 crore on a lower base.
- · Q2FY27 Services revenue declined 9% YoY, offset by 13% sequential growth, with Syngene reporting a 9% YoY revenue decline due to lower Zoetis revenues and forex hedge losses
- · Other income fell 63% YoY to Rs 34 crore, a major contributor to the flat total income growth
- · Depreciation and amortisation rose 19% YoY to Rs 563 crore, weighing on profitability
- · PBT before exceptional items fell 66% YoY to Rs 62 crore
- · Secured a ~USD 400 million 10-year Pertuzumab PDP partnership in Brazil and over USD 100 million in new US contracts
- · Pebrilzo (biosimilar Pertuzumab) received a positive CHMP opinion and earliest licensed launch dates across EU, UK, US and RoW under a Genentech settlement
04-11-2026
Workmates Core2Cloud Solution Limited reported consolidated revenue from operations of ₹9521.34 lakh for the half-year ended September 30, 2026, versus ₹7469.22 lakh in the corresponding period of the prior year, an increase of about 27.5% YoY. Consolidated profit for the period was ₹1203.40 lakh against ₹908.67 lakh a year earlier, up about 32.4%, with basic and diluted EPS of ₹9.32 versus ₹9.08. Sequentially, the half-year showed improvement over the March 31, 2026 half (revenue ₹6913.02 lakh, PAT ₹682.92 lakh), though the cost of cloud technology and other expenses rose in absolute terms.
- · Employee benefits expense was ₹1026.66 lakh, broadly flat versus ₹836.03 lakh a year earlier, rising about 22.8%.
- · Other expenses rose to ₹622.76 lakh from ₹420.24 lakh YoY (about 48.2%), a notable cost increase that weighed on margins.
- · Cost of Cloud Technology and Allied Services was ₹6328.62 lakh versus ₹4910.70 lakh YoY (about 28.9%), growing slightly faster than revenue.
- · Finance costs fell sharply to ₹0.50 lakh from ₹38.36 lakh YoY, reflecting reduced borrowing.
- · Paid-up equity share capital increased to ₹1291.88 lakh from ₹1001.00 lakh a year earlier.
- · Standalone profit for the period was ₹1178.13 lakh versus ₹933.17 lakh YoY, with standalone revenue of ₹9475.22 lakh.
04-11-2026
Dr. Lal PathLabs' Board, meeting on November 04, 2026, approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, declared a 2nd interim dividend of INR 5 per equity share (50% of face value of INR 10) with a record date of November 11, 2026, and appointed Ms. Vasuta Agarwal as a Non-Executive Independent Director for three years, subject to shareholder approval via postal ballot. The Board also approved a further investment of up to INR 49.5 Crore in its wholly owned UAE subsidiary Dr. Lal PathLabs FZCO, which may in turn invest up to INR 30 Crore in Ghana-based Sunshine Healthcare Limited.
- · Record date for 2nd interim dividend is November 11, 2026; payment to be made within 30 days of declaration
- · Ms. Vasuta Agarwal's appointment is subject to postal ballot approval; she is not debarred by SEBI or any other authority
- · Sunshine Healthcare Limited (Ghana) turnover declined from INR 244 Mn in FY 26 growth from INR 240 Mn in FY 25 (growth of about 1.7%) and INR 217 Mn in FY 24 (growth of about 10.6%)
- · Investment in LPL Dubai expected to complete by March 31, 2027; transactions are related party transactions on an arm's length basis
- · Operating cash flow growth was partly offset by a sharp rise in dividend payouts (+50%) and lower net investing outflows
- · Consolidated group added several entities during the period, including Shahbazkers Diagnostic Centre, Dr. Lal PathLabs FZCO, Sunshine Healthcare Ghana and Dr Lal Pathlabs Indomed LLC
04-11-2026
NDR Auto Components Limited filed its investor presentation for the quarter and six months ended 30 September 2026. Q2 FY27 Total Income rose 23.46% YoY to Rs. 247.86 Crore, EBITDA rose 21.68% to Rs. 27.47 Crore, and PAT rose 33.23% to Rs. 19.78 Crore; for H1 FY27, Total Income rose 21.69% to Rs. 470.41 Crore, EBITDA rose 25.29% to Rs. 53.92 Crore, and PAT rose 27.22% to Rs. 36.18 Crore. Standalone order book stood at Rs. 1,150 Crore as of 30 September 2026 after Rs. 540 Crore of Q2 FY27 order inflows, though management described the operating environment as challenging and ROCE excluding non-productive land and surplus cash declined from 31.07% to 36.52% in the opposite direction (improved) while overall ROCE margins were mixed at 8.0% versus 7.4%.
- · Expansion timelines: Seat Insert Support Fabric (Manesar, 6 Mn pcs p.a.), Seat Latch (Pathredi, 3 Mn pcs p.a.) and Seat Belt Reminder (Gujarat, 1.5 Mn pcs p.a.) all have expected SOP in Jan-27; Naviyani seat trims/frames (0.35 Mn pcs p.a.) expected Dec-27; Kharkhoda (1.5 Mn pcs p.a.) expected Oct-27
- · NDR Hayashi JV's Bengaluru facility commenced operations in June 2026, initially making sunshades, with target OEM customers Suzuki, Toyota and Honda
- · NDR-DYA JV (51% stake) supplies seating for Kia Seltos, Sportage and K9, Hyundai Casper, and KGM Rexton; the JV will be consolidated into NDR Auto
- · Safety-critical NDR Safety Systems Pvt Ltd Manesar plant is still under construction
- · Management described the operating environment as challenging, while noting efficiency gains helped sustain margins
04-11-2026
Manika Plastech Ltd's Board of Directors, at a meeting held on November 04, 2026, approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with the Limited Review Report from statutory auditors. The filing also confirms no deviation or variation in the utilisation of IPO proceeds (₹92.50 Cr fresh issue, allotted September 17, 2026) from the objects stated in the prospectus, as reviewed by the Audit Committee and Board. The filing does not disclose the headline P&L figures, so no growth comparisons can be made from this document.
- · Board meeting commenced at 1:34 PM and concluded at 1:50 PM on November 04, 2026
- · Brickwork Ratings India Private Limited is the monitoring agency for IPO fund utilisation
- · Of ₹81.64 Cr net proceeds, ₹18.79 Cr was utilised in the quarter across the four objects (plant and machinery ₹8.06 Cr, borrowings repayment ₹3.61 Cr, general corporate purposes ₹7.32 Cr, issue expenses ₹7.21 Cr)
- · Filing does not report revenue, profit, EPS, or other headline financial results figures despite referencing the results annexure
04-11-2026
Indo Count Industries reported consolidated revenue from operations of ₹1,67,265.35 Lakh (₹1,672.65 Cr) for Q2 FY27 (quarter ended 30-09-2026), up from ₹1,06,213.79 Lakh in the year-earlier quarter (+57.5% YoY) and up 38.6% sequentially from ₹1,20,696.20 Lakh in Q1. Consolidated profit for the period rose to ₹13,187.68 Lakh from ₹3,902.57 Lakh (+237.9% YoY), with basic/diluted EPS of ₹6.66 versus ₹1.97. However, the quarter was affected by flooding at the Bhilad, Gujarat facility, which resulted in an exceptional loss of inventory of ₹4,501.88 Lakh offset by an equal insurance claim recognised, and finance costs remained elevated at ₹3,661.20 Lakh. The statements were reviewed by Price Waterhouse Chartered Accountants LLP with an unmodified conclusion.
- · Consolidated finance costs rose to ₹3,661.20 Lakh in Q2 from ₹3,182.14 Lakh a year earlier (+15.0%), and standalone finance costs fell to ₹2,261.58 Lakh from ₹2,230.24 Lakh.
- · Consolidated cash and cash equivalents increased to ₹31,563.72 Lakh at 30-09-2026 from ₹11,356.37 Lakh at 31-03-2026, while consolidated trade payables (other than MSME) rose to ₹52,502.06 Lakh from ₹30,744.41 Lakh.
- · Labour code impact of ₹881.92 Lakh (gratuity) and ₹78.78 Lakh (compensated absences) was recognised as past service cost in FY26 under employee benefits expense.
- · Finance cost for FY26 included ₹1,281.81 Lakh of interest paid on delayed IGST refund following a Maharashtra GST search and inspection in March 2026.
- · Auditor's review noted that one subsidiary (with four step-down subsidiaries) contributed total revenue of ₹1,29,544.33 Lakh for the half year, and three unreviewed subsidiaries were judged not material by management.
04-11-2026
Consolidated Construction Consortium Limited (CCCL) has informed the NSE and BSE that its Registrar and Share Transfer Agent, KFin Technologies Limited, is changing its Corporate Office address effective 1 December 2026, and that KFin's Registered Office address is being updated to a Mumbai location with a new CIN. The notice is administrative in nature, with no financial figures, deals, or performance metrics disclosed.
- · Corporate Office of KFin Technologies Limited moves from Selenium Tower B, Plot 31-32, Gachibowli, Nanakramguda, Hyderabad 500032 to 6th Floor, South Tower, Rajapushpa West Avenue, Survey No. 115, Kokapet, Serilingampally Mandal, Ranga Reddy District, Telangana 500075, effective 1 December 2026
- · KFin's Registered Office address changes from Hyderabad to The Centrium, 3rd Floor, 57 Lal Bahadur Shastri Road, Kurla (West), Mumbai 400070, Maharashtra, with CIN changing from L72400TG2017PLC117649 to L72400MH2017PLC444072
- · KFin's toll-free/phone number (1800 309 4001) and email ([email protected]) remain unchanged
- · Filing made under Regulation 30 of the SEBI (LODR) Regulations, 2015, reference CCCL:SEC:2026-27/70
04-11-2026
Balrampur Chini Mills reported Q2 FY27 standalone revenue from operations of ₹187628.11 lakhs, up 14.6% QoQ from ₹163679.30 lakhs but up 12.3% YoY from ₹167076.34 lakhs, and H1 FY27 revenue of ₹351307.41 lakhs (up 9.3% YoY). Net profit for the quarter was ₹9592.79 lakhs, more than doubling YoY (from ₹4595.32 lakhs) and up 148.6% QoQ, while the Board also declared an interim dividend of ₹4.00 per share (400%). However, Q2 Polylactic Acid (PLA) segment results remained a loss-making drag at ₹(558.27) lakhs, and total borrowings rose to ₹154370.38 lakhs from ₹317,000-range levels at March 2026 mix shifts, with current borrowings falling sharply to ₹30298.45 lakhs.
- · Interim dividend of ₹4.00 per equity share declared; record date 11 November 2026; payment from 26 November 2026
- · Sugar segment Q2 FY27 profit before tax and finance costs rose to ₹14075.15 lakhs from ₹5284.31 lakhs YoY
- · Distillery segment profit fell 34.1% YoY in Q2 FY27 despite higher segment revenue
- · PLA segment losses widened sharply, to ₹(558.27) lakhs in Q2 FY27 from ₹(101.19) lakhs YoY
- · Inventories declined sharply to ₹71346.09 lakhs from ₹313461.68 lakhs at 31-03-2026, while cash and cash equivalents rose to ₹43586.87 lakhs
- · Capital work-in-progress increased to ₹253743.12 lakhs from ₹174707.35 lakhs, indicating ongoing capacity expansion
- · Board meeting held 1:00 PM to 2:30 PM on 4 November 2026; limited review (not audit) report issued by Lodha & Co LLP
04-11-2026
Diffusion Engineers Limited reported unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026, approved by the Board on 4 November 2026. Standalone Q2 FY27 revenue from operations was Rs. 1,080.78 million (up from Rs. 799.61 million in Q2 FY26, +35.2% YoY) and standalone PAT was Rs. 152.38 million (up from Rs. 99.13 million, +53.7% YoY). Consolidated Q2 revenue from operations was Rs. 1,259.34 million (up from Rs. 835.66 million, +50.7% YoY) and consolidated PAT was Rs. 127.53 million (up from Rs. 101.65 million, +25.5% YoY), while the quarter-on-quarter comparison shows consolidated PAT declining from Rs. 166.77 million in Q1 to Rs. 127.53 million. The statutory auditor issued an unmodified review opinion, with some subsidiaries and a foreign branch reviewed by other auditors or not reviewed.
- · Consolidated net profit declined sequentially from Rs. 166.77 million in Q1 FY27 to Rs. 127.53 million in Q2 FY27 (-23.5% QoQ), while standalone net profit fell from Rs. 99.79 million to Rs. 152.38 million (a 52.7% QoQ rise).
- · Consolidated share of profit/(loss) of associates and joint ventures was negative at Rs. (6.02) million in Q2 FY27 versus Rs. 44.59 million in Q1 FY27.
- · Standalone cash and cash equivalents declined to Rs. 759.82 million as at 30 Sep 2026 from Rs. 939.64 million as at 31 Mar 2026; consolidated cash fell to Rs. 792.62 million from Rs. 975.60 million.
- · Standalone net cash flow from operating activities was Rs. 57.73 million for the half year, versus Rs. 174.72 million for FY26; consolidated operating cash flow was Rs. 60.55 million versus Rs. 227.90 million, a substantial decline.
- · Standalone trade receivables fell to Rs. 880.05 million from Rs. 1,097.46 million, while inventories rose to Rs. 1,093.83 million from Rs. 673.63 million.
- · Standalone borrowings (short-term) increased to Rs. 291.32 million from Rs. 274.79 million; consolidated borrowings rose to Rs. 307.17 million.
- · Standalone other income fell to Rs. 97.72 million for the half year from Rs. 130.59 million in the prior-year half.
- · Standalone Dividend received from wholly owned subsidiary Diffusion Engineers Singapore Pte. Ltd. of USD 500,000 during the period.
- · Auditor's review of the standalone results includes a foreign branch not reviewed by the auditor (revenues Rs. 4.42 million for the quarter), and the consolidated review excludes results of seven subsidiaries reviewed by other auditors and foreign associates reviewed only by management.
- · ESOP scheme: 3,00,000 options granted at Rs. 325 per option on 25 Dec 2025, of which 1,00,000 were accepted, vesting in four equal tranches; the Trust holds 3,00,000 treasury shares.
04-11-2026
Balrampur Chini Mills Limited submitted a Monitoring Agency Report from India Ratings & Research for the quarter ended 30 September 2026 on its INR 450 Crore preferential issue (93,16,771 equity shares at INR 483 per share, issue period 20 May to 3 June 2026). The report confirms no deviation from the objects of the issue, with INR 170.74 Crore utilised in the quarter and cumulative utilisation of INR 321.36 Crore, leaving INR 128.64 Crore unutilised. The Gypsum Processing Plant (INR 110 Crore) has not yet seen any utilisation, while the PLA project is ongoing with an extended timeline.
- · The Gypsum Processing Plant (INR 110 Crore) shows zero utilisation to date and its completion deadline is 31 December 2027, which is later than the other objects.
- · The PLA project is marked on-going with a completion deadline of 31 December 2026, but the report flags it as a delayed object without stating reasons.
- · The General Corporate Purposes allocation of INR 110 Crore is listed as completed by 31 December 2026, with nil utilisation recorded in the quarter.
- · The Statutory Auditor Certificate supporting the report is dated 31 October 2026 (LODHA & CO LLP), and the MA states it did not independently verify source documents.
- · The fixed deposit at Axis Bank matures 4 July 2027, locking funds for a long period.
04-11-2026
Vikram Thermo (India) Ltd. reported standalone unaudited results for the quarter ended 30 September 2026, with Q2 FY27 revenue from operations of ₹4436.87 Lakh, up 28.1% YoY from ₹3463.53 Lakh, and Profit after tax of ₹1358.92 Lakh, up 22.7% YoY from ₹1107.66 Lakh. Half-year revenue rose to ₹8224.28 Lakh (up 30.0% YoY) and half-year PAT to ₹2687.08 Lakh (up 41.3%). Growth was partly offset by a sequential slowdown in Q2 versus Q1 (Revenue ₹3787.42 Lakh in Q1 FY27), and Cost of Materials Consumed rose 51.4% YoY in the quarter. The company also filed its related-party transactions disclosure for the half year and a Regulation 33 compliance letter.
- · Cost of materials consumed rose to ₹1713.13 Lakh in Q2 FY27 from ₹1131.97 Lakh a year earlier (about 51% increase), outpacing revenue growth
- · Employee benefit expense rose to ₹363.51 Lakh from ₹313.83 Lakh YoY, and Other expenditure rose to ₹644.61 Lakh from ₹461.45 Lakh YoY
- · Trade receivables increased to ₹5541.68 Lakh at 30 Sep 2026 from ₹4596.70 Lakh at 31 Mar 2026
- · Current investments rose to ₹2981.25 Lakh and Other bank balances to ₹1315.17 Lakh; total assets reached ₹22146.24 Lakh
- · Dividend paid in H1 FY27 was ₹36.49 Lakh versus ₹313.58 Lakh in H1 FY26
- · Limited review report issued by J. T. Shah & Co. with no material misstatement noted
- · Related-party remuneration to the Chairman & MD was ₹49.39 Lakh for the half year
04-11-2026
JTEKT India Limited reported Q2 FY27 (quarter ended 30 September 2026) revenue from operations of INR 83,474.26 lakh, up 30.6% YoY from INR 63,910.52 lakh, but down 16.3% QoQ from INR 71,798.38 lakh. Net profit after tax was INR 1,748.14 lakh, down 4.1% YoY from INR 1,822.77 lakh and sharply up from INR 622.19 lakh in Q1, while profit before tax fell 4.5% YoY to INR 2,385.29 lakh and employee costs and finance costs rose sharply. The Board also approved an investment of up to INR 2,40,00,000 (INR 240 lakh) for a 26% stake in a solar SPV to supply captive power to its manufacturing facilities.
- · Employee benefit expenses rose 16.1% YoY to INR 7,834.64 lakh, while finance costs rose 196.3% YoY to INR 562.74 lakh, pressuring margins despite higher revenue.
- · Q2 FY27 profit before tax (INR 2,385.29 lakh) was up 176.7% QoQ, but the company's effective tax burden rose: total tax expense was INR 637.15 lakh in Q2 FY27 versus INR 675.60 lakh in Q2 FY26.
- · Total liabilities increased to INR 88,247.96 lakh from INR 78,539.57 lakh at 31 March 2026, driven by non-current borrowings rising to INR 28,914.75 lakh from INR 19,909.63 lakh.
- · Trade receivables rose to INR 42,631.47 lakh from INR 37,786.16 lakh, and trade payables to creditors other than MSMEs rose to INR 36,919.83 lakh from INR 28,754.63 lakh.
- · Cash and bank balances fell sharply: bank balances other than cash equivalents went to nil from INR 3,400.00 lakh at 31 March 2026.
- · Other comprehensive loss widened to INR 135.55 lakh (pre-tax) on remeasurement of defined benefit obligations in H1 FY27 versus INR 88.44 lakh in H1 FY26.
- · The company has no subsidiaries, associates, or joint ventures as of 30 September 2026.
- · The solar SPV investment of up to INR 240 lakh is the sole disclosed use of the investment; the Share Purchase Agreement, Shareholders' Agreement, Performance Incentive Agreement and Energy Supply Agreement are yet to be executed and will be disclosed upon execution.
- · FY26 exceptional items (VSS cost INR 352.26 lakh and labour code gratuity past service cost INR 245.28 lakh) are non-recurring per management, but management will account for any further labour code impact as required.
04-11-2026
Amanta Healthcare Limited filed a Monitoring Agency Report from CRISIL Ratings for the quarter ended September 30, 2026, covering utilization of its IPO proceeds. Gross proceeds were Rs 12,600.00 lakh, with net proceeds revised to Rs 10,315.19 lakh after actual issue expenses of Rs 2,284.81 lakh exceeded estimates by Rs 358.38 lakh, absorbed by the general corporate purposes allocation. Of the Rs 10,082.69 lakh utilized in total (including issue expenses), Rs 2,517.31 lakh remains unutilized, while no deviations from the offer objects were reported.
- · SteriPort production from the capex was proposed to commence January 1, 2026; SVP production is proposed to commence January 1, 2027.
- · Vendor arrangements for civil construction, utilities and electrical works were modified from the prospectus, which the company says is consistent with the prospectus flexibility language.
- · Rs 181.42 lakh was moved to an SBI cash credit account for operational ease during the quarter and is reported as fully utilized.
- · Issue expenses and capex-related utilization were certified by a peer-reviewed chartered accountant certificate dated October 27, 2026.
- · Monitoring agency reported no deviation from objects, no change in means of finance, and no unfavorable or favorable events affecting object viability.
04-11-2026
Gaja Alternative Asset Management Ltd submitted its Monitoring Agency Report for the quarter ended September 30, 2026, issued by CARE Ratings Limited, covering utilisation of its IPO proceeds (Rs. 450.00 crore fresh issue, within a Rs. 550 crore total issue). Of the Rs. 450.00 crore, Rs. 92.78 crore was utilised in the quarter, leaving Rs. 357.22 crore unutilised, and the agency reported no deviations from the offer objects. The report is a routine regulatory compliance disclosure with no adverse findings.
- · Rs. 357.22 crore (79%) of the Rs. 450 crore fresh issue proceeds remained unutilised at September 30, 2026.
- · Board revised GCP deployment plan on September 03, 2026, accelerating Rs. 44.25 crore into FY27 versus the earlier phased schedule, with Rs. 39.40 crore used to repay an ICICI Bank overdraft.
- · Rs. 210 crore (proposed Fund V) and Rs. 105 crore (Secondaries Fund) sponsor commitments have not yet received any utilisation.
- · Rs. 19.50 crore bridge loan from ICICI Bank was drawn and repaid in full during the quarter.
- · Monitoring Agency Monitoring Agreement is dated July 23, 2026; IPO issue period ran August 19-21, 2026.
04-11-2026
Manaksia Coated Metals & Industries Limited filed the transcript of its Q2 and H1 FY'27 earnings conference call (held November 02, 2026) for the quarter and half-year ended September 30, 2026. Management reported record quarterly revenue, EBITDA and PAT, with Q2 total income of Rs. 321.55 crore (+43.8% YoY) and PAT of Rs. 18.73 crore (+32.9% QoQ), while flagging ongoing headwinds from geopolitical uncertainty, elevated raw material and freight costs, and a 4.4% rise in Q2 finance costs versus Q1 Rs. 6.86 crore to Rs. 8.48 crore.
- · Management stated FY'27 revenue is expected to rise 35%-55% over FY'26 (FY'26 revenue cited at around Rs. 896 crore by an analyst, not confirmed by management).
- · FY'28 volume could reach 175,000-200,000 tons with full-year capacity, though management declined a numerical revenue guidance for FY'28.
- · Second Colour Coating Line commissioning targeted within Q3 FY'27; solar plant expected to offset 50%-55% of Kutch grid power.
- · MES go-live targeted Q1 FY'28; Salesforce CRM targeted Q3 FY'27.
- · Q2 realization per ton was Rs. 95,291, EBITDA per ton Rs. 11,536, against Rs. 10,411 in Q1.
- · Management was unable to immediately address an analyst query on a 2024 SEBI adjudication order and deferred to the Company Secretary.
- · Management acknowledged geopolitical uncertainties and elevated raw material and freight costs as ongoing headwinds.
04-11-2026
Niva Bupa Health Insurance reported Q2 FY27 (quarter ended September 30, 2026) profit after tax of Rs. 13,564 lakh, up from Rs. 6,052 lakh a year earlier, and H1 profit of Rs. 27,344 lakh versus Rs. 13,196 lakh. Insurance revenue rose to Rs. 2,41,227 lakh for the quarter (from Rs. 1,89,907 lakh) and to Rs. 4,68,599 lakh YTD, while gross written premium grew to Rs. 2,48,405 lakh for the quarter. However, the sequential quarter saw profit slip modestly from Rs. 13,780 lakh, other comprehensive income turned negative (Rs. -13,851 lakh) on fair-value losses on debt instruments, and the solvency ratio declined to 2.03 from 2.85 a year earlier and 2.25 in the prior quarter. IRDAI also issued a warning and a six-month bar on opening new places of business over FY2024-25 expense-of-management (EoM) non-compliance, although the company reports compliance for FY2025-26 and the current period.
- · IRDAI order dated August 19, 2026 warned the company for FY2024-25 EoM non-compliance and bars opening new places of business for six months; the company accepted the order without appeal
- · Other comprehensive income was negative Rs. 13,851 lakh in the quarter, driven by fair-value losses on debt instruments of Rs. 18,516 lakh, versus positive Rs. 9,139 lakh in Q1 FY27
- · Solvency ratio fell to 2.03 from 2.25 in the prior quarter and 2.85 a year earlier
- · Deferred tax liabilities rose to Rs. 15,566 lakh from Rs. 7,968 lakh at March 31, 2026
- · Income tax demand of Rs. 12,716 lakh for four assessment years remains a contingent liability under appeal
- · Sequential quarterly profit was Rs. 13,564 lakh versus Rs. 13,780 lakh in Q1 FY27, a 1.6% decline
- · Results are subject to seasonality, so quarterly figures are not indicative of full-year performance
- · Investor complaints: none pending, received, or unresolved during the quarter
04-11-2026
Sangam Finserv Limited's Board of Directors met on 04 November 2026 (3:15 p.m. to 4:00 p.m.) and approved the Unaudited Financial Results for the quarter and half year ended 30 September 2026, along with the Statement of Assets and Liabilities, Statement of Cash Flows, and the Limited Review Report. The filing is the Board Meeting outcome intimation to BSE and the Calcutta Stock Exchange; the attached auditor's review report (O. P. Dad & Co.) states that nothing came to its attention indicating the results contain material misstatement, but the excerpt provided does not include the actual line-item figures, so no revenue, profit, or growth numbers can be reported.
- · Board meeting held 04 November 2026, concluded 4:00 p.m. at the registered office in Bhilwara, Rajasthan
- · Results cover the quarter and half year ended 30 September 2026 and are standalone (not consolidated)
- · Auditor's limited review conducted under SRE 2410 and Regulation 33 of SEBI LODR, providing moderate assurance only
- · Company is formerly known as Suchitra Finance & Trading Co. Ltd.
- · Figures for revenue, PAT, EPS, and year-over-year comparisons are not present in the provided content
04-11-2026
Advance Agrolife Limited reported revenue from operations of ₹2,871.53 Cr for the quarter ended September 30, 2026, up 35.0% year-over-year from ₹2,126.29 Cr, but down 13.1% sequentially from ₹3,304.04 Cr in the June 2026 quarter. Profit for the period was ₹117.94 Cr, up 25.7% YoY from ₹158.75 Cr but down 47.7% QoQ from ₹225.46 Cr, while basic and diluted EPS fell to ₹1.84 from ₹3.50 in the prior quarter and ₹3.53 a year ago, partly reflecting the increase in paid-up equity share capital to ₹642.86 Cr from ₹450.00 Cr.
- · Half-year revenue from operations rose to ₹6,175.58 Cr from ₹3,812.59 Cr (up 62.0% YoY), and half-year PAT rose to ₹343.40 Cr from ₹248.14 Cr (up 38.4%).
- · Cost of materials consumed rose to ₹2,362.56 Cr from ₹1,668.45 Cr YoY, and finance costs rose to ₹30.35 Cr from ₹21.58 Cr, pressuring margins.
- · Quarterly PBT fell to ₹159.71 Cr from ₹302.45 Cr in the June 2026 quarter (down 47.2% QoQ), and the current quarter's tax expense of ₹41.77 Cr compares with ₹76.99 Cr in the prior quarter.
- · Other equity excluding revaluation reserves stood at ₹2,456.28 Cr as of the year ended March 31, 2026.
04-11-2026
Mideast Portfolio Management Ltd reported standalone unaudited results for Q2 FY27 (quarter ended 30 September 2026) with revenue from operations of ₹801.85 Lacs, up sharply from nil in the prior-year quarter, driven by trading activity (purchase of stock-in-trade/cost of service availed of ₹772.26 Lacs). Profit before tax was ₹24.70 Lacs and profit for the period was ₹24.70 Lacs, compared with ₹14.80 Lacs in the prior-year quarter, a rise of about 67%. However, the quarter's profit was down sharply from the prior year's first-half figures and sequentially, and the company's revenue for the quarter came almost entirely from a single trading activity, with trade receivables of ₹841.25 Lacs and trade payables of ₹790.68 Lacs building up on the balance sheet.
- · Other income fell to nil in Q2 FY27 from ₹21.32 Lacs in Q2 FY26, while half-year other income was ₹7.62 Lacs versus ₹24.69 Lacs a year earlier.
- · Half-year profit for the period was ₹47.90 Lacs versus ₹136.83 Lacs in H1 FY26, a decline of about 65%, reflecting a prior-year tax-free profit base and the sharp drop in other income.
- · Trade receivables rose to ₹841.25 Lacs and trade payables to ₹790.68 Lacs as of 30 September 2026, against nil receivables and ₹42.63 Lacs payables at 31 March 2026.
- · Borrowings of ₹22.00 Lacs (non-current) appeared on the balance sheet, versus nil at 31 March 2026.
- · Cash and cash equivalents were ₹3.09 Lacs at 30 September 2026, down from ₹4.47 Lacs at 31 March 2026.
- · Net worth (total equity) stood at ₹496.68 Lacs, up from ₹448.83 Lacs at 31 March 2026, with other equity recovering from ₹(54.17) Lacs to ₹(6.32) Lacs.
- · Paid-up equity share capital shown as ₹503.00 Lacs in most columns but ₹445.07 Lacs in the half-year column, an inconsistency that may warrant clarification.
- · The Board has not recommended a dividend for FY 2025-26; results are unaudited and reviewed by the Audit Committee.
04-11-2026
Tijaria Polypipes Limited's Board approved standalone un-audited financial results for the quarter and half year ended September 30, 2026. The company reported no revenue from operations in any period, with total income of ₹3.30 Lacs for the quarter (vs. ₹10.06 Lacs in the year-ago quarter, a decline of about 67%) and a loss before tax of ₹30.97 Lacs, compared with a loss of ₹39.60 Lacs in the prior-year quarter. Net loss for the half year widened slightly to ₹67.08 Lacs from ₹66.22 Lacs, driven by a sharp rise in finance cost to ₹28.95 Lacs from ₹20.06 Lacs.
- · Revenue from operations was nil in all periods presented; income consists solely of other income (₹3.30 Lacs in the quarter).
- · Finance cost rose 21.8% to ₹28.95 Lacs for the half year, while depreciation fell to ₹34.33 Lacs from ₹38.19 Lacs.
- · Total equity is negative at ₹-3,446.04 Lacs, with retained earnings at ₹-12,185.68 Lacs.
- · Total borrowings (non-current ₹5,346.34 Lacs plus current ₹1,867.48 Lacs) remain large relative to total assets of ₹4,789.37 Lacs.
- · Term borrowings were repaid by ₹68.82 Lacs in the half year, and the prior-year half included a ₹500 Lacs repayment and loan recovery.
04-11-2026
Nykaa reported strong Q2 FY2027 results (quarter ended September 30, 2026), with consolidated GMV up 30% YoY to Rs. 6,151 Cr, Revenue from Operations up 28% YoY to Rs. 3,006 Cr, and PAT up 207% YoY to Rs. 101 Cr. EBITDA rose 65% YoY to Rs. 263 Cr, with margins expanding to 8.7% from 6.8%. The company also announced the acquisition of an 82% majority stake in celebrity makeup brand Simply Nam, subject to regulatory approvals and closing conditions.
- · Fashion EBITDA margin (% of NSV) improved from -3.5% in Q2 FY2026 to 0.2% in Q2 FY2027, turning positive
- · Superstore grew its registered retailer base 27% YoY while keeping business development executives constant, indicating productivity gains
- · NYKAA NOW expanded to 15 cities, targeting 25+ cities by end of FY2027, with an AOV 3X the BPC category on quick commerce
- · Strategic partnership with L'Oréal extended via BOLD to jointly invest in high-growth Indian beauty and personal care brands
- · Simply Nam acquisition is subject to regulatory approvals and closing conditions, so completion is not yet assured
- · Balanced view: profitability and growth were strong, but Fashion EBITDA margin remains only marginally positive (0.2%) and the Simply Nam deal is pending
04-11-2026
IRCON International reported standalone revenue from operations of ₹2,090.24 Cr for Q2 FY27 (quarter ended 30 Sep 2026), up from ₹1,853.15 Cr in the year-ago quarter (approximately +12.8% YoY), with standalone PAT of ₹121.92 Cr versus ₹184.67 Cr a year earlier (a decline of about 34%). Half-year revenue of ₹3,890.51 Cr compares with ₹3,515.72 Cr (+10.7%), while half-year PAT fell to ₹285.44 Cr from ₹335.24 Cr (-14.9%). The Board also noted an exchange fine for Q1 FY27 board/committee composition non-compliance, which the company argues is unreasonable because Government of India controls director appointments, and says a woman independent director was appointed on 17 August 2026 with committees reconstituted.
- · Exchange fine for Q1 FY27 non-compliance with Regulation 17(1), 18(1) and 19(1)/19(2) on Board and committee composition; company contends fine is unreasonable as the Government of India appoints directors
- · IRSDC voluntary liquidation: company received ₹5.96 Cr interim payment; investment carried at ₹65.42 Cr with no impairment perceived
- · Ircon-Soma Tollway concession ended 14 May 2026; its financials prepared on non-going-concern basis; company's 50% share of net worth ₹105.60 Cr, no impairment perceived
- · Three foreign branches (Algeria, Myanmar, Sri Lanka) with total assets of ₹815.72 Cr were reviewed by branch auditors, not the statutory auditor directly
- · Standalone EPS for the quarter stands at ₹1.30 basic versus ₹1.97 a year earlier, consistent with lower profit
04-11-2026
Lenskart Solutions Limited reported a 32.5% YoY increase in Q2 FY27 revenue to ₹2,845 crore (from ₹2,147 crore) and more than doubled profit after tax to ₹232 crore (from ₹113 crore). H1 FY27 revenue rose 33.0% to ₹5,559 crore and PAT reached ₹461 crore. Growth was broad-based, though the company's own disclosure flags currency headwinds from rupee depreciation, which it offset through in-house manufacturing.
- · Profit after tax more than doubled (up ~105%) YoY in Q2, a faster rate than revenue growth, indicating operating leverage
- · Company explicitly flagged continued rupee depreciation as a currency headwind, offset in part by in-house frame (+71.7%) and lens (+52.2%) manufacturing growth
- · International revenue growth of 29.5% was approximately 23% on a constant-currency basis, implying roughly 6-7 points of FX tailwind (note: the release describes this as a headwind for margins, not revenue)
- · Results are presented on a Proforma basis (adjusting for Dealskart, GeoIQ and Meller acquisitions) except ROCE, net working capital days and cash flow; reported and proforma figures converge from Q3 FY26 onward
- · Capital expenditure of ₹187 Cr in H1 FY27 versus operating cash flow of ₹388 Cr, showing self-funded expansion
- · Company will open a Meller store on Via del Corso in Rome later in November 2026
04-11-2026
Apollo Tyres' Board, meeting on November 4, 2026, approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, appointed Mr. Ravi Kumar Shingari as Chief Financial Officer effective the same day, and approved raising up to Rs.10,000 million via private placement of Non-Convertible Debentures, subject to shareholder approval by postal ballot. Consolidated revenue from operations for Q2 FY27 rose 16.7% YoY to Rs.79,681.50 million, but profit for the period fell 19.3% YoY to Rs.2,922.87 million, while sequential revenue growth of 7.7% was accompanied by a 16.2% sequential decline in profit.
- · Profit before exceptional items and tax fell 25.3% YoY in Q2 FY27 (Rs.4,230.28 million vs Rs.5,661.21 million), indicating core operating profitability weakened even as revenue grew.
- · Employee benefits expense rose to Rs.8,309.04 million in Q2 FY27 from Rs.8,785.70 million a year earlier (a 5.4% decline), while cost of materials consumed rose 33.9% YoY to Rs.42,414.23 million.
- · The Others segment's revenue fell 77.2% YoY to Rs.2,682.16 million, and Europe segment results fell 46.1% YoY, both flagged as underperforming in the segment disclosures.
- · Finance costs fell 6.7% YoY to Rs.942.39 million, partly offsetting margin pressure.
- · Paid-up debt capital rose sharply to Rs.43,160.33 million from Rs.27,150.54 million in Q1 FY27, a roughly 59% sequential increase, which the proposed NCD programme would add to further.
- · Exceptional items were a net charge of Rs.268.53 million in Q2 FY27 versus a Rs.1,800.37 million charge a year earlier.
- · Mr. Shingari joined in 2018 as Vice President - Accounts, Tax, Budgeting, Finance, Legal & Investor Relations, after more than 16 years at KPMG India as a Partner in Tax and Regulatory; he is a Chartered Accountant and law graduate and is not related to any other director.
04-11-2026
Vedanta Aluminium Metal Limited (VAML) informed exchanges that Employee Stock Option Grants 2023 under the pre-demerger Vedanta Limited ESOS 2016 have vested effective November 04, 2026, subject to performance conditions. A total of 55,16,340 options vested, of which 17,39,962 relate to VAML employees and 37,76,378 to VEDL and the three resulting companies, out of 1,84,14,252 options originally granted. Exercise price is at par value, exercise window is 8 months, and the exact number of options exercised, lapsed, and shares arising from exercise will only be determined after the exercise period closes.
- · The aluminium undertaking of Vedanta Limited was transferred to VAML under a Composite Scheme of Arrangement approved by NCLT Mumbai Bench, effective May 1, 2026
- · Vesting is contingent on completion of the performance period and achievement of performance conditions, based on business and individual performance over a sustained period
- · Exercise price is at par value, and the scheme is stated to be in terms of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
- · Exercised options, money realized, resulting shares, and lapsed options are yet to be determined and will be disclosed after the exercise period closes
- · No variation of option terms and no subsequent changes or cancellations have been reported
04-11-2026
Gateway Distriparks Limited filed the transcript of its Q2 FY27 earnings conference call (held October 28, 2026, jointly with Snowman Logistics Limited). Management expects rail volumes to continue at a similar trend, targeting a bare-minimum of 100,000 rail TEUs for the quarter and maintaining double-digit growth guidance for next year, while cautioning that Q1 took a big hit and full-year double-digit growth is uncertain. Snowman Logistics is on track to cross INR100 crore EBITDA this year, but PAT remains weighed down by reinvestment-driven interest and depreciation, and the 5PL segment grew only 1-2% with no new customers added this financial year.
- · Snowman 5PL: one major customer showed negative growth while others grew; one major customer's scope expanded from 2-3 geographies to pan-India
- · Snowman expects to add 23,000 pallets in the next few months and has a further 20,000+ pallets under discussion
- · Snowman warehouse capacity declined QoQ as some park-and-pay leases ended
- · Management acknowledged margin pressure from minimum wage hikes (Karnataka ~70%, Haryana ~35%), PF ceiling changes and gratuity impacts under the new wage code not yet passed through due to annual contracts
- · Snowman warehousing margins were stated as declining structurally since FY22 (from 18% to 16% per analyst), attributed by management to park-and-pay and build-to-suit mix
- · Ankleshwar EXIM permissions are now fully in place; Q3 expected to see volumes; management declined to share location-wise throughput
- · Indore ICD: civil and rail works underway, targeting operations by December 2027
- · Management said shipping lines have not yet indicated when they will increase calls to JNPT, making DFC-driven volume shift timing uncertain
04-11-2026
JM Financial Limited reported consolidated revenue of Rs. 1,056 crore and net revenue of Rs. 712 crore for Q2FY27, alongside an interim dividend of Rs. 1.65 per share. Net profit after tax declined 11% YoY to Rs. 240 crore, while net revenue was broadly flat YoY (Rs. 708 crore in Q2FY26) and cash and cash equivalents fell 7% to Rs. 2,753 crore. Investment banking profits grew 4x QoQ to Rs. 127 crore and the company ranked #1 by deal value across IPOs and QIPs for H1FY27, though MF average AUM for non-liquid schemes declined from Rs. 12,112 crore to Rs. 11,243 crore YoY.
- · Consolidated net worth rose 7% YoY to Rs. 10,993 crore, with BVPS up 7% to Rs. 114.9 after reducing goodwill of Rs. 52.4 crore
- · Debt/equity improved to 1.0x from 1.1x YoY
- · Mutual fund average AUM for non-liquid schemes declined 7.2% YoY, a notable underperforming segment
- · Standard loans in Private Markets grew 22% YoY to Rs. 4,748 crore, driven by the Bespoke vertical
- · Wealth management recurring AUM is up 20% from March 2026, indicating strong sequential momentum
- · Total dividend payout of Rs. 7.6 per share over the last six quarters
- · Consolidated loan AUM of ~Rs. 119.3 BN, distressed credit AUM of ~Rs. 106.7 BN, wealth management AUM of ~Rs. 1.14 TN and MF AAUM of ~Rs. 135.0 BN as of Sep 30, 2026
04-11-2026
JM Financial Limited's Board approved unaudited standalone and consolidated results for Q2 and H1 FY27 (quarter/half year ended September 30, 2026) and declared an interim dividend of ₹1.65 per share (face value ₹1). Consolidated Q2 total income was ₹1,056.15 Cr and net profit attributable to owners of the company was ₹239.54 Cr, versus ₹270.00 Cr in Q2 FY26 (a decline of roughly 11%), while H1 net profit attributable to owners was ₹531.46 Cr versus ₹723.81 Cr (down about 27%). Results are mixed: Corporate Advisory & Capital Markets and Wealth & Asset Management benefited from strong H1 segment performance in some areas, but consolidated profit and Q2 revenue from operations (₹1,032.22 Cr) fell year-on-year, and standalone H1 net profit rose to ₹258.43 Cr from ₹379.34 Cr in the prior-year half (a decline). The auditor's review reports are unmodified.
- · Standalone H1 FY27 total income was ₹483.94 Cr versus ₹643.43 Cr in H1 FY26, and standalone Q2 FY27 total income was ₹398.24 Cr versus ₹395.16 Cr in Q2 FY26.
- · Standalone Q2 FY27 net profit was ₹255.93 Cr versus ₹245.89 Cr in Q2 FY26 (up about 4%), but standalone Q1 FY27 net profit was only ₹2.50 Cr.
- · Consolidated Affordable Home Loans segment H1 FY27 results after execution of exceptional items were ₹34.60 Cr versus ₹49.84 Cr (down 31%), while Q2 FY27 rose to ₹22.74 Cr from ₹17.69 Cr.
- · Consolidated Corporate Advisory and Capital Markets Q2 FY27 segment result before exceptional items was ₹170.98 Cr versus ₹169.95 Cr in Q2 FY26 (roughly flat).
- · Interim dividend cash outflow of ₹157.91 Cr will fall in the quarter ending December 31, 2026, with record date November 11, 2026 and payment on or after November 20, 2026.
- · Tax-related exposure: JM Financial Services Limited has appealed ITAT orders on arbitrage-business disallowances for AY 2012-13 to 2014-15 to the Bombay High Court; the potential demand is likely material but cannot yet be quantified.
- · Paid-up equity share capital rose to ₹95.70 Cr after allotment of 45,000 shares to employees on stock option exercise during the quarter.
04-11-2026
GMM Pfaudler Limited's Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with a Limited Review Report from SRBC & COLLP. Consolidated revenue from operations for Q2 FY27 was Rs. 1,064.62 Crore, up 18.0% YoY from Rs. 902.34 Crore, though up 15.1% QoQ, while profit for the period was Rs. 35.13 Crore versus Rs. 37.68 Crore a year earlier, a 6.8% decline. The Board also appointed Mr. Ankit Nayyar as Group CFO and KMP effective November 4, 2026, following the early relieving of Mr. Alexander Poempner.
- · Q2 FY27 total expenses rose to Rs. 1,029.38 Crore from Rs. 849.44 Crore a year earlier, with employee benefits expense up to Rs. 287.61 Crore from Rs. 250.42 Crore.
- · Q2 FY27 finance cost was Rs. 31.44 Crore, up from Rs. 29.69 Crore YoY, and up sharply from Rs. 22.73 Crore in Q1 FY27.
- · Q2 FY27 current tax was Rs. 27.01 Crore versus Rs. 33.94 Crore in Q2 FY26, and deferred tax was a credit of Rs. 11.86 Crore.
- · Consolidated non-controlling interests contributed Rs. 1.83 Crore of profit in Q2 FY27 versus a loss of Rs. 2.16 Crore a year earlier.
- · Consolidated borrowings (non-current) declined to Rs. 456.79 Crore from Rs. 544.60 Crore as at March 31, 2026, while non-current lease liabilities rose to Rs. 311.68 Crore from Rs. 161.20 Crore.
- · Cash and cash equivalents stood at Rs. 426.55 Crore as at September 30, 2026, down from Rs. 635.38 Crore as at March 31, 2026.
- · Trade payables (other than MSMEs) rose to Rs. 565.36 Crore from Rs. 451.61 Crore since March 31, 2026.
- · Consolidated Q2 FY27 standalone-level figures are included in the filing but the excerpt provided shows only consolidated numbers; the standalone results and the balance sheet for prior periods were not fully visible.
- · Nonetheless, Mr. Nayyar's appointment followed Mr. Poempner's early exit for personal exigencies, a leadership transition at the CFO level effective the same day as the results.
04-11-2026
JK Lakshmi Cement filed its Q2 FY27 Investor Presentation under Regulation 30, following its earlier intimation of the earnings call schedule. Q2 FY27 sales volume was 28.43 lakh tonnes, up 5% YoY but down 17% QoQ, and net sales were ₹1,617 Crore, up 6% YoY but down 15% QoQ, with flat sales realisation at ₹4,885/MT versus the prior year. Profitability weakened sharply, with EBITDA of ₹259 Crore down 26% YoY and 40% QoQ, and PAT of ₹21 Crore down 75% YoY and 80% QoQ.
- · Capacity utilisation fell to 62% in Q2 FY27 from 65% in Q1 FY27 and 76% in Q2 FY26
- · Net debt rose to ₹1,225 Crore at 30.09.2026 from ₹611 Crore... (see note below)
- · Net Debt/EBITDA rose to 2.31 at 30.09.2026 from 0.51 at 31.03.2026 per company's debt profile slide, and Net Debt/Equity to 0.32 from 0.11 per the slide labels
- · Fuel cost rose to ₹1.65 per K.Cal in Q2 FY27 from ₹1.54 in Q2 FY26 (₹1.82 in Q1 FY27 per slide), while lead distance was 363 km versus 395 km in Q2 FY26
- · Green power share was 49% in Q2 FY27, with a FY30 target of 75%; FY30 target for low-carbon power mix is 65%
- · Grey cement capacity projected to grow from 18.0 MTPA in FY26 to 25.1 MTPA by FY30 (P), led by East zone expansion
- · Indian cement industry H1 FY27 volume growth estimated at 8–9%, with FY27 demand growth around 8%
04-11-2026
Suzlon Energy reported Q2 FY27 revenue of INR4,869 crore, up 27% QoQ from INR3,819 crore, with EBITDA of INR720 crore (up 21% QoQ) and PAT of INR394 crore (up 29% QoQ). On a YoY basis, WTG contribution margin declined from 26.9% to 21.2% and consolidated EBITDA margin fell to 14.8% versus 18.8% a year earlier, driven by customer/scope mix, forex and commodity volatility, and roughly INR80 crore of higher opex including about INR50 crore of non-recurring Suzlon 2.0 costs. Commissioning rose 69% QoQ to 454 MW, while H1 FY27 deliveries grew 21% YoY to 1,217 MW and H1 revenue grew 24% YoY to INR8,688 crore. Management flagged elevated working capital, a net cash position of about INR2,300 crore (with roughly 40-50% encumbered per the analyst's question, not confirmed by management), and a finance cost run-rate that is already above the earlier INR300 crore estimate by H1.
- · WTG contribution margin guided to remain in the 22-23% range for FY27, subject to normalization of FX and commodity headwinds
- · Normalized EBITDA margin guided at 16.5-17% excluding non-recurring Suzlon 2.0 costs, FX, commodity and West Asia impacts
- · Management guided full-year FY27 EBITDA margin of 15.1% plus up to 1% upside from H2 operating leverage (H2 expected at 1.5x-1.65x of H1)
- · Management stated FY27 finance cost is not expected to simply double H1 run-rate; interest cost on a like-to-like basis is said to be declining
- · Management guided a 25% CAGR trajectory with order book target of 15 GW by FY31 and annual sales near 10 GW
- · Deferred tax asset recognition will move to an annual exercise, with the next evaluation in March 2027
- · ASP in Q2 FY27 was about INR5.9 crore/MW versus INR5.7 crore/MW a year earlier; management said there was no price reduction
- · Receivables rose QoQ, with management attributing this to commissioning-linked holdbacks of 5-10% of revenue
04-11-2026
Gourmet Gateway India Limited reported standalone revenue from operations of ₹336.74 lacs for the quarter ended 30 September 2026, up from ₹277.95 lacs in the corresponding quarter of the prior year, and a standalone profit after tax of ₹8.06 lacs versus a loss of ₹3.89 lacs a year earlier. On a consolidated basis, revenue from operations rose to ₹5,495.31 lacs for the quarter (vs ₹4,742.01 lacs in the prior-year quarter, though the prior-year quarter figure appears to be the June 2026 comparative in the column order as printed), and consolidated profit after tax was ₹217.99 lacs versus ₹53.88 lacs. However, consolidated employee benefits expense and finance costs for the six-month period were flat-to-higher year over year, and the six-month consolidated profit after tax of ₹334.29 lacs compares with a loss of ₹12.56 lacs, reflecting improvement but with a sharp sequential moderation in standalone other expenses and a continuing ED money-laundering investigation affecting the group.
- · Standalone six-month revenue from operations declined to ₹614.69 lacs from ₹572.48 lacs in the prior year... (growth of approximately 7.4%, reported positively)
- · Standalone other expenses for the quarter fell sharply to ₹13.97 lacs from ₹21.99 lacs in the immediately preceding quarter and from ₹49.39 lacs in the quarter ended 30 Sep 2025 (the prior-year quarter column as printed)
- · Standalone employee benefits expense rose to ₹21.31 lacs for the six months from ₹12.90 lacs a year earlier, a flat-to-adverse cost trend
- · Consolidated employee benefits expense rose to ₹2,268.00 lacs for six months from ₹1,953.20 lacs (about 16% increase), outpacing revenue growth
- · Consolidated finance costs declined to ₹403.15 lacs for six months from ₹449.43 lacs
- · Standalone net cash used in operating activities was ₹16.20 lacs for six months, broadly unchanged from ₹16.03 lacs
- · Cash and cash equivalents on a consolidated basis rose to ₹690.02 lacs at 30 Sep 2026 from ₹533.92 lacs at 31 Mar 2026
- · Consolidated total equity increased to ₹7,038.50 lacs from ₹6,686.99 lacs; standalone Other equity was reported at ₹4,520.21 lacs
- · ED search and seizure under PMLA (FY 2024-25) remains in progress with a Provisional Attachment Order dated 05 September 2024 over promoter/promoter-group shares; management identifies no adjustment or disclosure impact, and the auditor draws attention to the matter without modifying its conclusion
- · Auditor reliance on other auditors' reviews covering eight subsidiaries (total assets ₹5,059.84 lacs) and one unreviewed subsidiary (immaterial to the Group)
- · Warrant holders of 38,27,743 warrants failed to pay the balance within eighteen months; ₹250.72 lacs forfeited and moved to capital reserve
- · Barista Coffee Mauritius Limited liquidated effective 26 June 2026
04-11-2026
EPACK Durable reported revenue from operations of INR439 crore for Q2 FY27, up more than 106% YoY from INR213 crore, and H1 FY27 revenue of INR1,325 crore, up 51.3% YoY, its highest ever first-half revenue. EBITDA was INR7.1 crore against INR0.5 crore a year earlier, with margin of 1.62% versus 0.23%, but management stated that the prior-year quarter included INR8 crore of PLI income and that excluding PLI the prior-year quarter EBITDA was negative INR7.5 crore. Gross margin on a like-for-like basis (excluding PLI) was 12.8% versus 12.4% last year, while a forex loss of approximately INR10 crore and lagged commodity pass-through continued to weigh on reported profitability.
- · Management attributed the lag in margin recovery to delayed commodity pass-through (passed in subsequent quarters under contracts) and a forex loss of approximately INR10 crore.
- · Gross debt is approximately INR770-775 crore, with leverage around 0.8x equity; management said the medium-term debt position will remain similar.
- · Epavo JV share of losses was INR12 crore over FY26 and H1 FY27, and the 50% stake transfer to Ram Ratna Group is for INR15 crore.
- · Two subsidiaries (Bumjin India Audio Products and EPACK Electronic Components Private Limited) are being wound up.
- · Pilot production of Hisense front-load washing machines is expected to finish by end of November 2026, with mass production from December.
- · Management said the PLI scheme for AC is in its final year and is in discussion for a possible extension; PLI discounts passed to brands will be rolled back in phases.
- · Top 2 customer concentration fell to 32% from 72% earlier in FY26; the company serves 72 customers across 19 categories.
- · Management did not provide explicit full-year or margin numeric guidance, declining to give forward-looking numbers.
04-11-2026
Apollo Hospitals reported consolidated revenue from operations of ₹76,149 Million (₹7,614.9 Cr) for Q2 FY27 (three months ended September 30, 2026), up from ₹61,868 Million in the corresponding quarter of the prior year (+23.1% YoY), and consolidated profit after tax of ₹6,595 Million, up from ₹4,940 Million (+33.5% YoY). Standalone revenue from operations rose to ₹26,561 Million from ₹23,561 Million (+12.7% YoY), and standalone PAT was ₹4,757 Million versus ₹4,199 Million (+13.3% YoY). Performance was mixed: standalone EBITDA margin and the discontinued pharmacy/retail-diagnostics divestment (ASPL/AFCPL) weighed on certain comparisons, and the Company also disclosed the cessation of Dr. Madhu Sasidhar as President & CEO – Hospitals Division effective November 14, 2026.
- · Consolidated EBITDA-type segment results: Healthcare services segment result rose to ₹7,600 Mn from ₹6,319 Mn (+20.3% YoY), while Digital health & pharmacy distribution segment result increased to ₹1,728 Mn from ₹859 Mn (+101.2% YoY).
- · Retail health & diagnostics segment result was ₹380 Mn versus ₹108 Mn a year earlier, but segment revenue was only ₹4,293 Mn, and a separate Retail health & diagnostics discontinued operations line item carries ₹5,306 Mn of assets held for sale against ₹7,049 Mn of associated liabilities.
- · Standalone other expenses rose to ₹9,203 Mn from ₹7,208 Mn (+27.7% YoY), outpacing standalone revenue growth of 12.7%.
- · Consolidated net cash from operating activities for six months rose to ₹14,933 Mn from ₹13,253 Mn (+12.7%), while standalone net cash from operating activities was ₹11,115 Mn versus ₹9,438 Mn.
- · Consolidated borrowings (current and non-current) totalled approximately ₹55,948 Mn, and consolidated trade receivables increased to ₹42,562 Mn from ₹34,849 Mn at March 31, 2026 (+22.1%), a rise that outpaced revenue growth on a sequential basis.
- · Consolidated discontinued operations (ASPL/AFCPL) recorded a profit before tax of ₹49 Mn in Q2 FY27, against a loss of ₹(66) Mn in Q2 FY26, and the divestment was completed on October 12, 2026 after CCI approval on September 1, 2026.
- · Labour Code implementation resulted in an exceptional item of ₹114 Mn (standalone) and ₹192 Mn (consolidated) for the year ended March 31, 2026, presented as non-recurring.
- · A Karnataka Revenue Department cancellation order on land grant conditions for subsidiary Imperial Hospitals & Research Centre Limited is under challenge; the High Court granted an interim stay on April 10, 2026, and the auditor's conclusion is not modified for this matter (emphasis of matter).
- · Deloitte Haskins & Sells LLP issued an unmodified review conclusion on both standalone and consolidated results, with reliance placed on other auditors' reviews for 28 subsidiaries and 1 joint venture plus 5 associates (consolidated), and 9 unreviewed subsidiaries.
- · Standalone basic EPS for Q2 FY27 was ₹33.08 versus ₹29.20 in Q2 FY26 (+13.3%), while the six-month standalone EPS was ₹59.86 versus ₹50.55 a year earlier.
- · Dr. Madhu Sasidhar's cessation as President & CEO – Hospitals Division takes effect after the close of business on November 14, 2026, and Dr. Ritu Garg, Anand Wasker and Dr. N. Venkatesan were designated Senior Management Personnel effective November 4, 2026.
04-11-2026
Patel Retail Limited reported unaudited results for the quarter and half year ended September 30, 2026. Revenue from operations for Q2 FY27 was ₹29,860.47 lakh (₹298.60 Cr), down from ₹30,953.51 lakh in the immediately preceding quarter but up 34.2% versus ₹22,244.41 lakh in the same quarter last year, while PAT of ₹991.15 lakh declined 2.2% year-over-year from ₹1,013.96 lakh. Profit before tax rose only marginally versus the year-ago quarter (₹1,321.18 lakh vs ₹1,351.98 lakh, a decline of 2.3%), and the company's own notes say the new lease accounting (Ind AS 116) and depreciation method change distort comparability with the prior year, flattering PBT by about ₹170.94 lakh in June 2026 alone.
- · Half-year revenue from operations of ₹60,813.98 lakh rose about 50.2% versus ₹40,489.83 lakh in H1 FY26, but half-year PAT grew only about 13.8% to ₹1,942.75 lakh from ₹1,706.38 lakh.
- · Basic and diluted EPS fell to ₹3.59 in Q2 FY26 comparison: current-quarter EPS of ₹2.97 declined from ₹3.59 a year earlier (about -17.3%), and half-year EPS was ₹5.82 versus ₹6.42.
- · Depreciation rose to ₹484.92 lakh in Q2 FY27 from ₹314.09 lakh a year earlier, partly due to ROU asset recognition (₹300.34 lakh depreciation impact for the quarter).
- · Finance cost was broadly flat at ₹249.83 lakh versus ₹288.62 lakh a year earlier, a decline of about 13.4%, while employee benefit expenses rose about 37.9% to ₹1,267.19 lakh.
- · Cash and cash equivalents fell to ₹383.77 lakh at September 30, 2026 from ₹472.50 lakh at March 31, 2026, and net cash flow from operating activities for the half year was ₹3,101.14 lakh versus an outflow of ₹(8,606.82) lakh a year earlier.
- · IPO fund utilisation: of ₹21,710.70 lakh gross IPO proceeds (incl. pre-IPO ₹1,500 lakh), ₹20,883.07 lakh had been utilised by September 30, 2026, leaving ₹827.63 lakh unutilised in General Corporate Purposes; escrow balance is ₹926.31 lakh including ₹96.60 lakh payable to promoters for an OFS.
- · Audit Committee and Board approved results on November 4, 2026; the auditor's limited review status is not explicitly stated in the excerpt, and the company reports no deviation in use of IPO funds.
04-11-2026
Oswal Agro Mills Limited's Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and declared an interim dividend of Rs 0.50 per equity share (face value Rs 10) for FY 2026-27. Standalone total income for Q2 FY27 was ₹13,700 Lakh (₹137 Cr) versus ₹4,350 Lakh in the prior-year quarter, driven by real estate and investment activity, while standalone expenses for the half year rose sharply and half-year profit before tax fell from ₹1,821.71 Lakh to ₹1,054.38 Lakh, with the Q2 pre-tax result up but profit after tax for the half year down from ₹1,335.47 Lakh to ₹760.62 Lakh.
- · Board approved an interim dividend of Rs 0.50 per equity share (face value Rs 10) for FY 2026-27, first communicated in an October 30, 2026 letter.
- · Standalone real estate segment revenue for Q2 FY27 was ₹8,795.4 Lakh, arising from sale of approximately 84.52% of the BMC TDR parcel.
- · Half-year standalone operating cash flow was negative (about ₹8,449.26 Lakh outflow), and cash and cash equivalents declined to ₹1,836.75 Lakh from ₹6,706.57 Lakh at March 31, 2026.
- · Auditor's review report issued unmodified conclusion with no material misstatement identified; predecessor auditor Mehta Choksi & Shah LLP reviewed prior periods.
- · Figures in the source table are partially garbled by OCR; amounts above are reported as they appear in the filing and should be verified against the original PDF.
04-11-2026
Esha Media Research Limited reported unaudited results for the quarter and half year ended September 30, 2026, with revenue from operations of ₹82.28 Lakh for the quarter (vs ₹46.39 Lakh a year earlier, a rise of about 77%) and a net loss of ₹29.39 Lakh (vs ₹65.19 Lakh loss a year earlier, a narrowing of about 55%). However, the half-year loss widened to ₹94.57 Lakh from ₹74.21 Lakh, and net worth remains fully eroded with total equity of ₹(206.97) Lakh, and the statutory auditors issued a qualified conclusion with going-concern uncertainty.
- · Auditors expressed a qualified audit conclusion on the quarterly financial results in regard to an outstanding interest-free unsecured loan of ₹98.50 Lakh from a member.
- · Net worth is fully eroded and current liabilities exceed current assets, indicating significant uncertainty over going concern; promoters/management have committed to infuse funds as required.
- · Preferential allotment of 10,00,000 equity shares at ₹15 to promoters, plus 70,00,000 and 1,69,00,000 convertible warrants at ₹15 each; 25% (₹3.75 per warrant) received upfront, balance ₹11.25 per warrant due within 18 months.
- · Company is regularising past procedural compliances under SEBI LODR and Companies Act 2013 for monies received from parties; financial impact not yet quantifiable.
- · Borrowings (Inter-Corporate Deposits) reduced to ₹164.50 Lakh from ₹612.50 Lakh; ₹70.00 Lakh invested in investments during the half year.
- · Other equity improved to ₹(1,087.66) Lakh from ₹(1,824.93) Lakh, while equity share capital rose to ₹880.69 Lakh from ₹780.69 Lakh.
04-11-2026
Ravindra Energy Limited reported standalone Q2 FY27 (quarter ended September 30, 2026) revenue from operations of ₹1262.20 Million, up 23.8% YoY from ₹1019.37 Million, and standalone PAT of ₹290.11 Million, down 8.6% YoY from ₹317.23 Million. Half-year standalone revenue fell 11.2% YoY to ₹2180.58 Million and half-year PAT fell 23.8% to ₹427.66 Million, while consolidated half-year revenue rose 8.0% to ₹3103.02 Million but consolidated PAT fell 55.6% to ₹206.80 Million after a 186.98 Million share-of-loss from Joint Venture. The results include restated prior-period figures following a change in accounting policy for solar plants under Ind AS 115 Service Concession Arrangements, and the company raised ₹2013.60 Million through a rights issue and ESOP exercises.
- · Consolidated quarterly revenue from operations rose 80.4% YoY to ₹1903.33 Mn, but consolidated quarterly PAT fell 21.9% YoY to ₹190.45 Mn, weighed down by a ₹69.72 Mn share of loss from the Joint Venture.
- · Standalone other equity rose to ₹4885.18 Mn as at Sept 30, 2026 from ₹2653.05 Mn at March 31, 2026, while standalone borrowings (non-current) increased to ₹445.79 Mn from ₹20.18 Mn.
- · Consolidated borrowings (non-current) rose to ₹6542.48 Mn from ₹4745.59 Mn, and consolidated financial costs for the half year rose to ₹277.37 Mn from ₹124.75 Mn (up 122.4%).
- · Standalone net cash flow from operating activities turned negative at ₹(8.62) Mn for the half year versus ₹708.23 Mn a year earlier, while investing outflows were ₹(2809.62) Mn.
- · Monitoring Agency CARE Ratings reported no deviation from the objects of the rights issue (aggregating ₹200.53 crore) for the quarter ended Sept 30, 2026.
- · Auditor's review report includes an emphasis of matter on the change in accounting policy and restatement of prior-period comparatives; the statutory auditor's review of Thirty Seven subsidiaries, Eighteen LLPs and one JV relied on other auditors' reports.
04-11-2026
Hariom Pipe Industries reported standalone revenue from operations of ₹55,424.00 lakh for Q2 FY27 (quarter ended September 30, 2026), up 65.0% YoY from ₹33,586.74 lakh, and standalone profit after tax of ₹2,852.33 lakh, up 173.9% YoY from ₹1,041.56 lakh. Half-year revenue rose 23.4% YoY to ₹98,342.30 lakh, while sequential quarterly revenue grew 29.1% from ₹42,918.30 lakh in Q1, a quarter in which the Tamil Nadu plant was temporarily shut by the TNPCB. Consolidated results were broadly in line, with consolidated PAT of ₹2,527.79 lakh for the quarter; however, consolidated borrowings rose sharply to ₹22,855.78 lakh non-current and standalone finance costs increased 28.1% YoY to ₹1,699.17 lakh, and the company carries a large current borrowing balance of ₹29,543.55 lakh.
- · Standalone Q2 FY27 operating expenses for power and fuel rose 61.6% YoY to ₹2,543.26 lakh, a cost pressure that weighed on margins
- · Standalone Q2 FY27 cost of materials consumed rose sharply YoY to ₹45,364.28 lakh from ₹25,970.91 lakh, consistent with the revenue increase
- · Standalone trade payables rose to ₹11,715.40 lakh and borrowings remain high, with non-current borrowings of ₹14,300.42 lakh and current borrowings of ₹29,543.55 lakh
- · Standalone cash and cash equivalents fell to ₹23.01 lakh from ₹554.02 lakh a year earlier, indicating tight liquidity
- · Standalone net cash from operating activities for the half year was ₹3,310.58 lakh, down from ₹4,056.59 lakh, while investing outflows widened to ₹10,840.62 lakh
- · Consolidated net profit attributable to owners was ₹2,537.01 lakh for the quarter, slightly below standalone PAT because of subsidiary losses and non-controlling interest effects
- · The warrant balance of ₹3,858.09 lakh (75% of ₹5,145.45 lakh) is payable on or before January 27, 2028, representing a future cash inflow contingent on conversion
- · Auditors issued unmodified limited review conclusions on both standalone and consolidated results, with no material misstatements noted
04-11-2026
Uniparts India Limited filed its Q2 FY27 earnings presentation for the quarter and half year ended September 30, 2026. Management reported record quarterly revenue from operations of ₹379 crore, up 36.7% YoY and 9.0% QoQ, with PAT of ₹54.4 crore (up 38.2% YoY) but down 3.9% QoQ. Sequentially, EBITDA margin contracted to 23.1% from 25.3% and gross margin fell to 65.7% from 66.6%, while large agriculture growth (+10% YoY) lagged construction (+49% YoY) and small agriculture (+25% YoY) and the aftermarket contribution was volatile.
- · Gross profit margin compressed to 65.7% from 69.4% a year earlier, indicating rising input costs
- · Q2 FY27 PBT and PAT both declined sequentially (-2.3% and -3.9%) despite record revenue
- · Large agriculture grew only 10% YoY against a ~17% industry volume decline, and management flagged aftermarket purchasing as discretionary and volatile quarter to quarter
- · Management expects small agriculture growth to be flat to +5% in the US and Canada, flat in Europe, and +4% to +6% in India
- · Ludhiana finishing shop restoration is expected to be operational by end of calendar 2026; first Mexico customer dispatch scheduled for November 2026
- · Revenue mix as of H1 FY27: 3PL 43% and PMP 55% of finished goods sales; OEM accounted for 54.2% of market presence
04-11-2026
Ellenbarrie Industrial Gases Limited's Board approved unaudited results for the quarter and six months ended September 30, 2026, reviewed by statutory auditors with an unmodified conclusion. Q2 FY27 total income rose to ₹1,314.29 Cr versus ₹1,017.84 Cr in the year-ago quarter (approx. 29% growth), and revenue from operations rose about 28% YoY to ₹1,143.18 Cr, with profit after tax up about 0.8%-to ₹356.47 Cr versus ₹367.17 Cr, reflecting a sharp rise in power costs and depreciation. Six-month PAT of ₹706.09 Cr grew about 27% YoY, while Q2 PAT was marginally lower than Q2 FY26 and the quarter-on-quarter comparison was broadly flat.
- · Q2 FY27 PAT of ₹356.47 Cr was about 2.9% below Q2 FY26 (₹367.17 Cr), even though revenue grew about 28%, driven by power expenses rising about 40% YoY and depreciation rising about 37% YoY
- · Project Engineering revenue fell about 81% YoY in Q2 to ₹2.34 Cr and its segment result turned negative at ₹(9.94) Cr
- · Other income rose to ₹171.11 Cr in Q2 from ₹126.11 Cr a year earlier (about 36% growth), and interest income for H1 was ₹303.67 Cr versus ₹159.06 Cr
- · Current borrowings fell about 46% to ₹649.91 Cr from ₹1,206.95 Cr at March 31, 2026, while non-current borrowings rose to ₹735.58 Cr
- · Capital work-in-progress was fully capitalised, falling from ₹779.04 Cr to nil, with PP&E rising to ₹5,492.24 Cr
- · Cash and cash equivalents were only ₹2.66 Cr at September 30, 2026, against a cash flow from operations of ₹436.26 Cr for H1
- · Reported 'Total liabilities' of ₹2,871.36 Cr is a non-trivial item, and the segment liabilities table shows Q1 FY27 unallocated liabilities of ₹1,502.91 Cr versus ₹1,011.62 Cr at Q2 end, indicating volatility in unallocated items
- · Basic and diluted EPS was ₹2.53 for Q2 FY27 versus ₹2.61 in Q2 FY26 (down about 3%), and ₹5.01 for H1 FY27 versus ₹4.07 (up about 23%)
04-11-2026
Northern Arc Investment Managers Private Limited (NAIM), the asset management subsidiary of Northern Arc Capital Limited, announced the first close of its Northern Arc Diversified Debt Fund with commitments exceeding ₹400 Crore, targeting a ₹1,500 Crore corpus with a ₹500 Crore greenshoe option (up to ₹2,000 Crore) and a 16% XIRR target over a five-year tenure. The same day, the company announced that the Northern Arc India Impact Fund matured with a 14.59% Gross XIRR, in line with targeted returns, though the fund's return is below the 16% target set for the new fund.
- · The Diversified Debt Fund is rated AA (SO) by CareEdge Ratings, with a five-year tenure; the rating does not eliminate credit risk per the disclaimer
- · The India Impact Fund supported 60 businesses across credit cycles, deploying gross capital of ₹1398 Crore at fund level
- · Seven of the 15 funds launched since 2014 have fully matured, with no extensions or principal loss to investors
- · The India Impact Fund's 14.59% return sits below the 16% target now set for the Diversified Debt Fund
- · The company has facilitated approximately INR 2.7 lakh Crore of financing and manages INR 21,790 Crore of total assets (figures as of September 30, 2026)
- · The release includes forward-looking target returns and explicit risk disclaimers stating returns are not assured and past performance is not indicative of future results
04-11-2026
Apollo Hospitals reported standalone unaudited results for the quarter and half year ended 30 September 2026, with Q2 FY27 revenue from operations of ₹26,561 Million (vs ₹23,561 Million in Q2 FY26 per the table, a 12.7% YoY rise) and six-month revenue of ₹55,590 Million (up 22.9% YoY from ₹45,240 Million). Profit after tax for the half year rose 18.4% to ₹8,607 Million, but quarterly PAT declined 9.1% sequentially from ₹4,199 Million to ₹4,757 Million in Q2, while the sequential Q2 PAT increase versus Q1 (₹3,852 Million) was strong. The Board also announced CEO-level leadership changes and completion of the Cloudnine (KCIL) divestment on 3 November 2026.
- · Dr. Madhu Sasidhar ceases as President & CEO - Hospitals Division and SMP effective close of business 14 November 2026
- · Support functions and other regions previously reporting to the President & CEO now report to the Project Management Office under the Managing Director
- · Q2 FY27 PAT declined sequentially from ₹3,852 Mn? No: Q1 FY27 PAT was ₹3,852 Mn, so Q2 PAT rose sequentially by 23.5%
- · Q2 FY27 standalone EBITDA of ₹7,226 Mn, up 21.9% YoY from ₹5,929 Mn
- · Trade receivables rose to ₹10,493 Mn from ₹8,473 Mn at 31 Mar 2026 (+23.8%), and operating cash flow was ₹11,115 Mn (+17.8% YoY)
- · Capex (purchase of PP&E, CWIP and intangibles) rose to ₹6,655 Mn in H1 FY27 from ₹3,422 Mn in H1 FY26, nearly doubling
- · Divestment of ASHPL and AFCPL to KCIL closed on 3 November 2026; both have ceased to be subsidiaries of AHLL
04-11-2026
Apollo Hospitals Enterprise Limited reported standalone revenue from operations of ₹26,561 Mn in Q2 FY27 (quarter ended September 30, 2026), up 12.7% YoY from ₹23,561 Mn, while standalone PAT rose 13.3% YoY to ₹4,757 Mn. Consolidated revenue from operations grew 23.1% YoY to ₹76,149 Mn and consolidated PAT attributable to owners rose 32.0% YoY to ₹6,299 Mn, with mixed signals in the balance sheet: consolidated trade receivables increased to ₹42,562 Mn from ₹34,849 Mn at March 31, 2026, and standalone profit before tax growth (+12.3%) trailed the strong consolidated revenue expansion.
- · Consolidated results include discontinued operations (Apollo Specialty Hospitals and Apollo Fertility Centre), with discontinued operations contributing a loss of ₹90 Mn in Q1 FY27 and a profit of ₹49 Mn in Q2 FY27.
- · Exceptional item of ₹114 Mn (standalone) and ₹192 Mn (consolidated) relating to increased gratuity and leave liabilities under the Labour Codes effective November 21, 2025 was recognised in the prior year period.
- · Standalone net cash from operating activities rose to ₹11,115 Mn for H1 FY27 from ₹9,438 Mn, while consolidated capex on PP&E and intangibles increased to ₹11,999 Mn from ₹7,065 Mn.
- · Consolidated borrowings stood at ₹24,487 Mn non-current and ₹31,461 Mn current at September 30, 2026, versus ₹24,301 Mn and ₹32,284 Mn at March 31, 2026.
- · A Karnataka High Court matter relating to land allotment to subsidiary Imperial Hospitals & Research Centre Limited remains pending, with an interim stay granted on April 10, 2026; the auditor flagged it without modifying its conclusion.
- · Dr. Madhu Sasidhar ceases as President & CEO - Hospitals Division effective close of business November 14, 2026; Dr. Ritu Garg, Anand Wasker and Dr. N. Venkatesan are designated Senior Management Personnel from November 4, 2026.
04-11-2026
Electrotherm (India) Limited's standalone revenue from operations for Q2 FY27 (quarter ended 30 September 2026) was Rs. 912.43 crore, roughly flat versus Rs. 913.38 crore in Q1 and up from Rs. 814.26 crore in the year-ago quarter. The company posted a net loss after tax of Rs. 20.06 crore for the quarter (versus a net loss of Rs. 21.71 crore in Q2 FY26) and a half-year net loss of Rs. 13.20 crore, against a half-year profit of Rs. 5.97 crore a year earlier. The Board also approved a variation of powers for Managing Director Shailesh Bhandari (redesignated Executive Vice Chairman, term to 31 January 2031, subject to shareholder approval via postal ballot), while the filing discloses ongoing loan defaults, a Rs. 1148.28 crore understatement of liability to Rare ARC, and a new ED provisional attachment.
- · Standalone total expenses for Q2 FY27 were Rs. 940.70 crore, exceeding total income of Rs. 913.31 crore, driving the quarterly pre-tax loss of Rs. 27.39 crore
- · Finance costs fell sharply to Rs. 2.61 crore in Q2 FY27 from Rs. 7.18 crore a year earlier, partly offsetting operating pressure
- · Earnings per share for Q2 FY27 were Rs. (15.74) basic and diluted, versus Rs. 5.39 in Q1 FY27 and Rs. (17.04) in Q2 FY26
- · Employee benefit expenses rose to Rs. 64.00 crore in Q2 FY27 from Rs. 58.11 crore a year earlier
- · Auditor has issued a qualification in the limited review report over non-provision of interest on the Rare ARC loan
- · Enforcement Directorate complaint under PMLA names the Company, Shailesh Bhandari and Mukesh Bhandari; the Company and promoters have challenged the actions before the Gujarat High Court, which is pending adjudication
- · Trade receivables, trade payables, advances and tax balances remain subject to confirmation, reconciliation or final assessment
04-11-2026
ITI Limited held its 76th Annual General Meeting on 4 November 2026 via video conferencing, with 58 members in attendance. Shareholders considered seven resolutions, covering adoption of FY2025-26 audited financial statements, reappointment of Shri C V Ramana Babu as Director, authorisation for Statutory Auditor remuneration, appointment of three new directors (two Government Directors and one Director Production), and Cost Auditor remuneration for FY2026-27. The meeting ran from 12:30 pm to 1:57 pm IST, and voting results and the Scrutiniser's report are due within two working days.
- · Remote e-voting ran from 1 November 2026 (09:00 am) to 3 November 2026 (05:00 pm), with e-voting also available during the AGM and for 15 minutes after its conclusion
- · Shri Rajesh Rai, Chairman and Managing Director, addressed the Company's FY2025-26 performance, current-year performance and future plans, and fielded member queries on performance, future steps and cost-cutting measures
- · Resolution 4 proposes appointing Lt. Gen. Vivek Dogra as Government Director, Resolution 5 appoints Shri Ajai Kumar Srivastava as Director Production, and Resolution 6 appoints Shri Sanjiwan Sinha (DoT) as Government Director
- · The Authorised Representative of the President of India and Governor of Karnataka attended the meeting
Get daily alerts with 12 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 50 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: India Stock Market Daily Regulatory Digest
November 02, 2026
India Stock Market Daily Regulatory Digest — November 02, 2026
November 01, 2026
India Stock Market Daily Regulatory Digest — November 01, 2026
October 31, 2026
India Stock Market Daily Regulatory Digest — October 31, 2026
October 30, 2026
India Stock Market Daily Regulatory Digest — October 30, 2026
🇮🇳 More from India
View all →November 05, 2026
India Upcoming Corporate Actions BSE NSE — November 05, 2026
India Upcoming Corporate Actions BSE NSE
November 05, 2026
India Pre-Market Regulatory Roundup — November 05, 2026
India Pre-Market Regulatory Roundup
November 05, 2026
India Quarterly Results BSE NSE Announcements — November 05, 2026
India Quarterly Results BSE NSE Announcements
November 04, 2026
India Quarterly Results BSE NSE Announcements — November 04, 2026
India Quarterly Results BSE NSE Announcements